目的：本文主要通过研究心力衰竭大鼠不同中医证型HFABP（heart-type fatty acid-binding protein ,HFABP）的含量变化,说明中医证型和HFABP的关系,从而为中医证型找到客观依据,促进中医理论的客观化.方法：无特殊病原体（SPF）普通级雄...目的：本文主要通过研究心力衰竭大鼠不同中医证型HFABP（heart-type fatty acid-binding protein ,HFABP）的含量变化,说明中医证型和HFABP的关系,从而为中医证型找到客观依据,促进中医理论的客观化.方法：无特殊病原体（SPF）普通级雄性Wistar大鼠40只,体重200±20g,将其随机分为四组：生理盐水对照组10只,心力衰竭模型2周组、4周组及8周组各10只.将各组大鼠进行中医辨证分型,并测定各组中医证型大鼠HFABP的含量.结果：大鼠各组中医证型的HFABP含量有显著性差异（P＜0.05）.结论：说明中医证型与HFABP密切相关,可能为中医证型找到一个新的客观依据.展开更多
Objective:This study aims to investigate whether the heart fatty acid-binding protein(HFABP)in the cerebrospinal fluid(CSF)was a potential predictive biomarker for Alzheimer’s disease(AD).Methods:We evaluated the ass...Objective:This study aims to investigate whether the heart fatty acid-binding protein(HFABP)in the cerebrospinal fluid(CSF)was a potential predictive biomarker for Alzheimer’s disease(AD).Methods:We evaluated the associations of CSF HFABP levels with core biomarkers,cognition,and brain structure in a sample population(n=302)from the Alzheimer’s Disease Neuroimaging Initiative(ADNI)database.Multiple linear regression and mixed-effects models were employed in the analyses.AD progression was assessed using the Kaplan–Meier survival analysis.Results:CSF HFABP was higher in patients with mild cognitive impairment and AD than the normal controls(p<0.001)and was particularly higher in those with amyloid-β(Aβ)pathologic features.CSF HFABP was associated with higher baseline CSF t-tau(p<0.001),CSF p-tau(p<0.001),and CSF t-tau/Aβ42 and CSF p-tau/Aβ42(p<0.01).Moreover,CSF HFABP was found to play predictive roles in hippocampal atrophy(p<0.01),cognitive decline(p<0.05),and the risk of AD(p<0.001).Conclusion:Our findings suggest that CSF HFABP can be a predictive biomarker of AD.展开更多
文摘目的：本文主要通过研究心力衰竭大鼠不同中医证型HFABP（heart-type fatty acid-binding protein ,HFABP）的含量变化,说明中医证型和HFABP的关系,从而为中医证型找到客观依据,促进中医理论的客观化.方法：无特殊病原体（SPF）普通级雄性Wistar大鼠40只,体重200±20g,将其随机分为四组：生理盐水对照组10只,心力衰竭模型2周组、4周组及8周组各10只.将各组大鼠进行中医辨证分型,并测定各组中医证型大鼠HFABP的含量.结果：大鼠各组中医证型的HFABP含量有显著性差异（P＜0.05）.结论：说明中医证型与HFABP密切相关,可能为中医证型找到一个新的客观依据.
基金funded by the Alzheimer’s Disease Neuroimaging Initiative(ADNI)(National Institutes of Health Grant U01 AG024904)DOD ADNI(Department of Defense award number W81XWH-12-2-0012)funded by the National Institute on Aging,the National Institute of Biomedical Imaging and Bioengineering
文摘Objective:This study aims to investigate whether the heart fatty acid-binding protein(HFABP)in the cerebrospinal fluid(CSF)was a potential predictive biomarker for Alzheimer’s disease(AD).Methods:We evaluated the associations of CSF HFABP levels with core biomarkers,cognition,and brain structure in a sample population(n=302)from the Alzheimer’s Disease Neuroimaging Initiative(ADNI)database.Multiple linear regression and mixed-effects models were employed in the analyses.AD progression was assessed using the Kaplan–Meier survival analysis.Results:CSF HFABP was higher in patients with mild cognitive impairment and AD than the normal controls(p<0.001)and was particularly higher in those with amyloid-β(Aβ)pathologic features.CSF HFABP was associated with higher baseline CSF t-tau(p<0.001),CSF p-tau(p<0.001),and CSF t-tau/Aβ42 and CSF p-tau/Aβ42(p<0.01).Moreover,CSF HFABP was found to play predictive roles in hippocampal atrophy(p<0.01),cognitive decline(p<0.05),and the risk of AD(p<0.001).Conclusion:Our findings suggest that CSF HFABP can be a predictive biomarker of AD.
